Medical treatment in cystic echinococcosis is limited; albendazole remains the gold treatment for patients with low hydatid cysts or those with inoperable echinococcosis. Due to uncommon side effects, administration may be continuous (cycles of 28 days with a break of 14 days between courses) as well as discontinuous over long periods of time. In recent years, there have been many concerns for the testing of various substances and drugs against Echinococcus granulosus, both in vitro and in vivo, on the animal model, but the results have not been satisfactory. New clinical trials are required, as well as the development of an effective vaccine to limit the spread of echinococcosis in endemic areas.
Part of the book: Overview on Echinococcosis